Hania (Donepezil Hydrochloride)

Hania is indicated for the symptomatic treatment of Alzheimer’s disease in adults. It may be prescribed when a clinician determines that cholinergic enhancement could benefit cognitive function.

• Improves memory and attention in patients with mild to moderate Alzheimer’s disease.
• May help maintain daily living activities for a limited period.
• Used as part of a comprehensive treatment plan that includes non‑pharmacologic interventions.
• Considered when other cholinesterase inhibitors are not suitable or tolerated.
• Prescribed by a healthcare professional after diagnosis confirmation.

Side effects of Hania can vary in frequency and severity. Patients should be aware of both common and serious reactions.

Common

• Nausea, vomiting, or loss of appetite.
• Diarrhea or abdominal cramps.
• Insomnia or vivid dreams.
• Muscle cramps or weakness.

Serious

• Bradycardia or heart block.
• Severe dizziness leading to falls.
• Allergic reactions such as rash, swelling, or difficulty breathing.

Before starting Hania, certain precautions should be considered to ensure safe use. Patients should discuss their medical history with a healthcare provider.

• Evaluate cardiac history, especially bradyarrhythmias.
• Review liver function, as hepatic impairment may affect metabolism.
• Caution in patients with asthma or chronic obstructive pulmonary disease.
• Monitor for signs of gastrointestinal bleeding.
• Assess for potential interactions with other cholinergic or anticholinergic agents.
• Use with caution in elderly patients due to increased fall risk.

Hania may interact with other medications, affecting its efficacy or safety profile. Some combinations should be avoided, while others require careful monitoring.

Avoid

• Concurrent use with other acetylcholinesterase inhibitors.
• Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin.
• Medications that significantly lower heart rate, like beta‑blockers or digoxin.

Use with caution

• Anticholinergic drugs (e.g., antihistamines, tricyclic antidepressants) that may counteract its effect.
• NSAIDs or anticoagulants, which could increase gastrointestinal bleeding risk.